Top Regulatory Challenges When Entering the Asian Pharmaceutical Market

Asia is the world’s fastest-growing pharmaceutical region. It is also the most regulatory complex. Those two facts are not unrelated.

The Asian pharmaceutical market represents one of the most significant commercial opportunities in global life sciences. By 2025, the region accounts for approximately 35% of global pharmaceutical sales, with markets across Japan, China, South Korea, Singapore, Taiwan, and Southeast Asia collectively driving demand that no serious market access strategy can afford to ignore. Yet the organisations that enter these markets successfully are not simply the ones with the best products. They are the ones that understood the regulatory landscape before they committed resources to it.

The challenges are real, they are well-documented, and — critically — they are navigable. Here is what the data and the operational reality actually look like.

🌏 Challenge 1: Regulatory Fragmentation Across Jurisdictions

The single most structurally defining feature of the Asian pharmaceutical market is that there is no unified regulatory framework. Unlike the European Medicines Agency model — where a centralised procedure can deliver marketing authorisation across multiple member states — Asia operates as a collection of sovereign regulatory systems, each with its own legislation, submission format, data requirements, and review timelines.

The principal regulatory authorities and their governing frameworks include:

Each of these systems has distinct requirements for dossier format, clinical data localisation, labelling standards, and post-approval change management. An organisation that treats Asian market entry as a single regulatory exercise — rather than a portfolio of eight or more separate regulatory engagements — will encounter delays, rejections, and resource expenditure that was entirely foreseeable.

The data on this is unambiguous. A 2023 industry survey by the Asia-Pacific Economic Cooperation (APEC) Regulatory Harmonisation Steering Committee found that regulatory fragmentation was cited as the primary market access barrier by 68% of pharmaceutical companies operating across three or more Asian markets simultaneously. The cost of managing parallel dossiers, country-specific translations, and jurisdiction-specific variations was estimated at USD 2.3 million per product per market entry cycle for mid-sized pharmaceutical organisations.

📋 Challenge 2: Clinical Data Localisation Requirements

Several major Asian regulatory authorities require — or strongly prefer — clinical data generated in local patient populations. This is not a bureaucratic preference. It reflects genuine pharmacogenomic and epidemiological considerations, particularly for conditions where disease prevalence, genetic polymorphisms, and standard-of-care differ meaningfully between Asian and Western populations.

Japan has historically maintained the most stringent bridging study requirements under the PMDA framework. Although the 2014 revision to the PMDA’s guidance on foreign clinical data acceptance has progressively reduced the mandatory bridging study burden, the PMDA still requires applicants to demonstrate that foreign clinical data is applicable to the Japanese population — either through a bridging study or through a robust scientific justification based on pharmacokinetic and pharmacodynamic comparability.

China’s NMPA underwent a landmark reform in 2017 when it joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). This reform substantially accelerated the acceptance of foreign clinical data for innovative drug applications. However, for traditional Chinese medicines, biologics, and products in therapeutic areas with high local disease burden, the NMPA continues to require China-specific clinical evidence. The 2019 Drug Administration Law further reinforced requirements for post-marketing clinical studies in Chinese populations for certain product categories.

South Korea’s MFDS applies a risk-stratified approach to clinical data localisation. Innovative drugs with robust global clinical packages and ICH-compliant dossiers can often proceed without local bridging studies. Generic and biosimilar applications, however, face bioequivalence study requirements conducted in Korean subjects — a requirement that adds both time and cost to the development programme.

The operational implication is significant: organisations that do not plan for clinical data localisation requirements at the development stage — not the registration stage — consistently face the longest approval delays in Asian markets. A 2024 analysis of PMDA approval timelines found that applications requiring post-submission bridging study data took an average of 14.3 months longer to reach approval than applications with complete clinical packages at the time of submission.

⏱️ Challenge 3: Review Timelines and Queue Management

Regulatory review timelines across Asian markets vary enormously — and the published timelines frequently diverge from operational reality.

The gap between official targets and operational reality is not random. It is driven by three consistent factors:

1. Query management — the volume and complexity of questions raised by regulatory reviewers during the assessment process, and the speed with which applicants respond with complete, accurate answers
2. Dossier quality at submission — incomplete or inconsistent dossiers generate disproportionate query volumes and restart internal review clocks in several jurisdictions
3. Regulatory resource constraints — several Asian regulatory authorities are managing submission volumes that have grown faster than reviewer capacity, particularly following the post-COVID acceleration of pharmaceutical development pipelines

The query management point deserves particular emphasis. A 2023 analysis of NMPA innovative drug applications found that applications receiving more than three rounds of queries took an average of 26.7 months to reach approval — compared to 16.4 months for applications resolved within two query rounds. The difference is almost entirely attributable to dossier quality and applicant response speed, not regulatory processing time.

🔬 Challenge 4: Good Manufacturing Practice Compliance and Facility Inspection

Every major Asian regulatory authority requires that pharmaceutical products are manufactured in facilities compliant with Good Manufacturing Practice (GMP) standards. The challenge is that GMP recognition is not universally reciprocal across Asian markets.

Japan recognises GMP certificates issued under the PIC/S framework and accepts foreign manufacturing site inspections conducted by PIC/S member authorities. However, the PMDA also conducts its own foreign manufacturing site inspections for products seeking Japanese marketing authorisation — a process that adds both time and logistical complexity for manufacturers outside Japan.

China’s NMPA has progressively moved toward international GMP alignment following ICH membership, but continues to conduct independent GMP inspections of overseas manufacturing facilities for products registered in China. The NMPA’s overseas inspection programme has expanded significantly since 2019: overseas GMP inspections increased by 43% between 2020 and 2024, reflecting both the growing volume of foreign drug applications and heightened regulatory scrutiny of manufacturing quality.

Indonesia’s BPOM requires that all pharmaceutical products registered in Indonesia are manufactured in facilities that have received a BPOM GMP certificate — a requirement that necessitates a BPOM facility inspection regardless of existing PIC/S or other international GMP certifications. This is one of the most frequently cited market access barriers for organisations entering the Indonesian market, adding six to eighteen months to the registration timeline for facilities not previously inspected by BPOM.

The practical implication for market entry planning: GMP compliance documentation and facility inspection readiness must be assessed as part of the pre-submission strategy, not treated as a post-submission administrative step. Organisations that discover GMP inspection requirements after submission consistently experience the longest and most costly delays.

🌐 Challenge 5: Regulatory Harmonisation — Progress, Limits, and What It Means in Practice

The Asian pharmaceutical regulatory landscape is not static. Harmonisation initiatives have made genuine progress in reducing — though not eliminating — the fragmentation burden.

ASEAN Harmonisation The ASEAN Common Technical Dossier (ACTD) format provides a standardised dossier structure accepted across ASEAN member states. This reduces the document preparation burden for organisations entering multiple Southeast Asian markets simultaneously. However, ACTD harmonisation covers format, not substance — each member state retains its own data requirements, review processes, and approval timelines.

ICH Membership Expansion The expansion of ICH membership to include China (2017), South Korea (2016), and Taiwan (2018) has substantially improved the acceptance of internationally generated clinical and non-clinical data in these markets. For innovative drug applications with robust global clinical packages, ICH membership has meaningfully reduced the localisation burden.

APEC Regulatory Harmonisation The APEC Regulatory Harmonisation Steering Committee (RHSC) continues to advance mutual recognition frameworks and regulatory capacity-building across member economies. Progress is incremental but directionally consistent.

The honest assessment: harmonisation has reduced the regulatory fragmentation burden but has not resolved it. Organisations that plan Asian market entry strategies on the assumption that harmonisation has created a unified regional pathway will encounter the same fragmentation challenges that have defined this market for decades — just with updated dossier formats.

💡 What Successful Asian Market Entry Actually Looks Like

The organisations that navigate Asian pharmaceutical regulatory challenges most effectively share a consistent set of operational characteristics:

• Early regulatory intelligence — market-specific regulatory requirements are assessed at the development planning stage, not at the point of submission preparation
• Jurisdiction-specific dossier strategies — each market receives a tailored submission strategy based on its specific requirements, not a globally standardised package adapted at the margins
• Proactive query management — internal processes for rapid, complete, and accurate responses to regulatory queries are established before submission, not improvised after the first query letter arrives
• GMP readiness assessment — manufacturing facility GMP compliance is assessed against each target market’s specific requirements as part of the pre-submission workstream
• Realistic timeline planning — market access timelines are built on operational median data, not official target timelines, with contingency built in for query rounds and re-inspection requirements

The Asian pharmaceutical market rewards preparation with speed. It penalises assumptions with delays that compound across every market in the portfolio simultaneously.